Content by Sino Biological

Emily Peng from Sino Biological highlights how time-resolved fluorescence resonance energy transfer (TR-FRET) enhances assay sensitivity and throughput for reliable drug screening.

Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST

Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.

Designed to balance ease of use, cost efficiency, and reproducible data, which are critical requirements for successful high-throughput screening campaigns

A better understanding of immune checkpoint signaling can help improve future checkpoint inhibitor therapeutic approaches. 

One-stop end-to-end solutions support researchers at all stages of CAR T-cell therapy development.

In this symposium, an expert panel will discuss how the latest organoid models help researchers discover and develop new drugs. 

This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.

Having the right reagents and tools accelerates autoimmune disease research.

Choosing the right 3D culture components and validation steps helps researchers unlock accurate, reproducible, and relevant insights into cancer biology.

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).